Induction of labor with mifepristone (RU 486) in intrauterine fetal death
| Autor: | André Ulmann, D. Ulmann, Dominique Cabrol, H. Cronje, A. Treisser, Catherine Dubois, S. Correl, Jack Moodley, J. M. Thoulon, J.M. Gonnet, M. Guillot, B. Maria, J. F. Oury |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
medicine.medical_specialty Time Factors medicine.medical_treatment Double-Blind Method Pregnancy Oxytocics Humans Multicenter Studies as Topic Medicine Labor Induced Fetal Death Abortifacient Disseminated intravascular coagulation Gynecology Chemotherapy Fetus business.industry Obstetrics Antagonist Obstetrics and Gynecology Drug Tolerance Mifepristone Induction of labor medicine.disease In utero Female business medicine.drug |
| Zdroj: | American Journal of Obstetrics and Gynecology. 163:540-542 |
| ISSN: | 0002-9378 |
| DOI: | 10.1016/0002-9378(90)91193-g |
| Popis: | In a double-blind controlled multicentric study involving 94 patients with an intrauterine fetal death, we investigated the efficacy and tolerance of mifepristone (RU 486), a steroid compound that antagonizes progesterone action at the receptor level. Success of treatment was defined as the occurrence of fetal expulsion within 72 hours after the first drug intake. Mifepristone treatment (600 mg per day for 2 days) was considered to be effective in 29 of 46 patients (63%). There were only eight successes in 48 patients (17.4%) in the placebo group ( p = 0.001, χ 2 test). Tolerance was good in the mifepristone group. In the placebo group, disseminated intravascular coagulation occurred in one woman for whom the investigator waited several weeks for spontaneous expulsion. This large double-blind controlled study provides evidence that mifepristone is of interest in the management of intrauterine fetal death. It could provide a pharmacologic alternative to the use of prostaglandins in this indication. Key words: Mifepristone, intrauterine fetal death, induction of labor |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|